dyskinesia (LID) can be improved by adjusting the dosage to find a tolerable balance between the benefits and side effects. These movements fluctuate in severity throughout the day but there is no reliable way of objectively monitoring them at home. This means that clinicians have very scant clinical information to base treatment decisions on, resulting in a series of 'trial and error' drug regimen changes, and delayed optimal management.
The intervention that was assessed is ClearSky's LID-Monitor which demonstrates the severity of involuntary movements in relation to drug doses, enabling clinicians to make informed decisions regarding altering complex drug regimens. The intervention involves patients wearing small sensors and carrying a mobile phone in their pocket for 24 hours.
The objective of this study was to assess the cost effectiveness of implementing LIDMonitor in Parkinson's patients with dyskinesia.
Parameter
Value Source An early stage cost-effectiveness model was developed from a UK National Health Service (NHS) perspective. The decision tree model examined implementation of LID-Monitor compared to current practice over one year (Figure 1) .
The model considers the incident population, the proportion of patients that are wellcontrolled or poorly-controlled, the number of falls, healthcare resource use and utility associated with dyskinesia. The model inputs were derived from published literature and where no data were available clinical expert opinion was elicited from clinicians experienced in the disease area and use of the device ( 
RESULTS AND CONCLUSIONS
The model estimated that implementing LID-Monitor resulted in a dominant incremental 
